These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31290799)

  • 21. Low-dose Aripiprazole Induced Enuresis Continuum in a Child.
    Karatoprak S; Uzun N
    Clin Neuropharmacol; 2020; 43(4):123-124. PubMed ID: 32541331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute dystonia associated with aripiprazole overdose in an adolescent boy.
    Kubota K; Yamamoto T; Orii K; Shinoda S; Fukao T
    Asian J Psychiatr; 2017 Oct; 29():183-184. PubMed ID: 28697462
    [No Abstract]   [Full Text] [Related]  

  • 23. Aripiprazole-Induced Hoarseness: A Case Report.
    Işik Ü; Çam Ray P
    Clin Neuropharmacol; 2019; 42(2):55-56. PubMed ID: 30724787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.
    Jordan S; Koprivica V; Chen R; Tottori K; Kikuchi T; Altar CA
    Eur J Pharmacol; 2002 Apr; 441(3):137-40. PubMed ID: 12063084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats.
    Li M; Budin R; Fleming AS; Kapur S
    Psychopharmacology (Berl); 2005 Sep; 181(3):600-10. PubMed ID: 16025315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypical antipsychotic overdose in the pediatric population.
    Catalano G; Catalano MC; Nunez CY; Walker SC
    J Child Adolesc Psychopharmacol; 2001; 11(4):425-34. PubMed ID: 11838825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.
    De Berardis D; Fornaro M; Serroni N; Marini S; Piersanti M; Cavuto M; Valchera A; Mazza M; Girinelli G; Iasevoli F; Perna G; Martinotti G; Di Giannantonio M
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):30-7. PubMed ID: 24372345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aripiprazole for autism spectrum disorders (ASD).
    Ching H; Pringsheim T
    Cochrane Database Syst Rev; 2012 May; (5):CD009043. PubMed ID: 22592735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging role of aripiprazole for treatment of irritability associated with autistic disorder in children and adolescents.
    Stachnik J; Gabay M
    Adolesc Health Med Ther; 2010; 1():105-14. PubMed ID: 24600266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies.
    Madhusoodanan S; Brenner R; Gupta S; Reddy H; Bogunovic O
    CNS Spectr; 2004 Nov; 9(11):862-7. PubMed ID: 15520608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aripiprazole.
    Fleischhacker WW
    Expert Opin Pharmacother; 2005 Oct; 6(12):2091-101. PubMed ID: 16197361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole versus other atypical antipsychotics for schizophrenia.
    Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
    Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of atypical antipsychotics in the treatment of autistic disorder.
    Stachnik JM; Nunn-Thompson C
    Ann Pharmacother; 2007 Apr; 41(4):626-34. PubMed ID: 17389666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aripiprazole-induced sleep-related eating disorder: a case report.
    Kobayashi N; Takano M
    J Med Case Rep; 2018 Apr; 12(1):91. PubMed ID: 29622043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of the safety and tolerability of aripiprazole.
    Pae CU
    Expert Opin Drug Saf; 2009 May; 8(3):373-86. PubMed ID: 19505266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder.
    Findling RL; Mankoski R; Timko K; Lears K; McCartney T; McQuade RD; Eudicone JM; Amatniek J; Marcus RN; Sheehan JJ
    J Clin Psychiatry; 2014 Jan; 75(1):22-30. PubMed ID: 24502859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of pediatric atypical antipsychotic exposures reported to U.S. poison centers.
    Stassinos G; Klein-Schwartz W
    Clin Toxicol (Phila); 2017 Jan; 55(1):40-45. PubMed ID: 27644404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overdoses with Aripiprazole: Signs, Symptoms and Outcome in 239 Exposures Reported to the Danish Poison Information Centre.
    Christensen AP; Boegevig S; Christensen MB; Petersen KM; Dalhoff KP; Petersen TS
    Basic Clin Pharmacol Toxicol; 2018 Feb; 122(2):293-298. PubMed ID: 28881461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.